Drug intelligence / Profile preview

CNTY-104

Development stage: Unknown
Lead developer: Century Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CNTY-104 is an allogeneic, multi-specific, induced pluripotent stem cell (iPSC) derived chimeric antigen receptor (CAR)-natural killer (NK) cell therapy. It is genetically engineered to target hematologic malignancies such as acute myeloid leukemia. CNTY-104 is categorized as an antineoplastic, CAR-NK, CAR-T, gene therapy, immunotherapy, and iPSC-derived cell therapy. Its mechanism involves immunologic cytotoxicity and replacement of natural killer and T lymphocytes, designed to kill tumor cells by harnessing the innate cytotoxic capabilities of NK cells modified with CAR constructs[1][5][9].

Brand names: CNTY-104CNTY104CNTY 104
Other names: CNTY-104CNTY104CNTY 104

Beyond the preview

Go deeper on CNTY-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNTY-104.

Explore the full profile